Cargando…
Adoptive cell therapy for cancer treatment
Adoptive cell therapy (ACT) is a rapidly growing anti‐cancer strategy that has shown promise in treating various cancer types. The concept of ACT involves activating patients’ own immune cells ex vivo and then transferring them back to the patients to recognize and eliminate cancer cells. Currently,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624386/ https://www.ncbi.nlm.nih.gov/pubmed/37933232 http://dx.doi.org/10.1002/EXP.20210058 |
_version_ | 1785130913773912064 |
---|---|
author | Du, Shi Yan, Jingyue Xue, Yonger Zhong, Yichen Dong, Yizhou |
author_facet | Du, Shi Yan, Jingyue Xue, Yonger Zhong, Yichen Dong, Yizhou |
author_sort | Du, Shi |
collection | PubMed |
description | Adoptive cell therapy (ACT) is a rapidly growing anti‐cancer strategy that has shown promise in treating various cancer types. The concept of ACT involves activating patients’ own immune cells ex vivo and then transferring them back to the patients to recognize and eliminate cancer cells. Currently, the commonly used ACT includes tumor‐infiltrating lymphocytes (TILs), genetically engineered immune cells, and dendritic cells (DCs) vaccines. With the advancement of cell culture and genetic engineering techniques, ACT has been used in clinics to treat malignant hematological diseases and many new ACT‐based regimens are in different stages of clinical trials. Here, representative ACT approaches are introduced and the opportunities and challenges for clinical translation of ACT are discussed. |
format | Online Article Text |
id | pubmed-10624386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106243862023-11-05 Adoptive cell therapy for cancer treatment Du, Shi Yan, Jingyue Xue, Yonger Zhong, Yichen Dong, Yizhou Exploration (Beijing) Perspectives Adoptive cell therapy (ACT) is a rapidly growing anti‐cancer strategy that has shown promise in treating various cancer types. The concept of ACT involves activating patients’ own immune cells ex vivo and then transferring them back to the patients to recognize and eliminate cancer cells. Currently, the commonly used ACT includes tumor‐infiltrating lymphocytes (TILs), genetically engineered immune cells, and dendritic cells (DCs) vaccines. With the advancement of cell culture and genetic engineering techniques, ACT has been used in clinics to treat malignant hematological diseases and many new ACT‐based regimens are in different stages of clinical trials. Here, representative ACT approaches are introduced and the opportunities and challenges for clinical translation of ACT are discussed. John Wiley and Sons Inc. 2023-07-02 /pmc/articles/PMC10624386/ /pubmed/37933232 http://dx.doi.org/10.1002/EXP.20210058 Text en © 2023 The Authors. Exploration published by Henan University and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Perspectives Du, Shi Yan, Jingyue Xue, Yonger Zhong, Yichen Dong, Yizhou Adoptive cell therapy for cancer treatment |
title | Adoptive cell therapy for cancer treatment |
title_full | Adoptive cell therapy for cancer treatment |
title_fullStr | Adoptive cell therapy for cancer treatment |
title_full_unstemmed | Adoptive cell therapy for cancer treatment |
title_short | Adoptive cell therapy for cancer treatment |
title_sort | adoptive cell therapy for cancer treatment |
topic | Perspectives |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624386/ https://www.ncbi.nlm.nih.gov/pubmed/37933232 http://dx.doi.org/10.1002/EXP.20210058 |
work_keys_str_mv | AT dushi adoptivecelltherapyforcancertreatment AT yanjingyue adoptivecelltherapyforcancertreatment AT xueyonger adoptivecelltherapyforcancertreatment AT zhongyichen adoptivecelltherapyforcancertreatment AT dongyizhou adoptivecelltherapyforcancertreatment |